Tag
PRMT5 inhibition sensitizes B-cell lymphomas to ferroptosis by disrupting the PRMT5-ATF5-SLC7A11 axis, offering a novel therapeutic strategy for relapsed or refractory disease.
This review synthesizes clinical trial evidence for Axicabtagene Ciloleucel, tracing its development from refractory B-cell lymphoma to its current role as a second-line standard and its expansion into indolent and mantle cell lymphomas.
A novel grading system, T-ICAHT, quantifies thrombocytopenia after CAR T-cell therapy, revealing its prevalence and prognostic impact, highlighting its value in patient management and outcome prediction across hematologic malignancies.
FT516, an iPSC-derived NK cell therapy, shows promising safety and efficacy in relapsed or refractory B-cell lymphoma, potentially overcoming key limitations of existing cell therapies.
